Literature DB >> 16686707

Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.

Dorothea Weckermann1, Marcus Goppelt, Robert Dorn, Friedhelm Wawroschek, Rolf Harzmann.   

Abstract

OBJECTIVE: To investigate how many men with low-risk prostate cancer had positive lymph nodes detected by radio-guided surgery and whether they had a higher biochemical relapse rate after radical prostatectomy, because in such patients most urologists dispense with operative lymph node staging, as nomograms indicate only a low percentage of lymph node metastases. PATIENTS AND METHODS: The study included 474 men with a prostate-specific antigen (PSA) level of < or = 10 ng/mL, biopsy Gleason score of < or = 6 and positive biopsies in one (group 1, 315 men) or both lobes (group 2, 159 men); follow-up data were available in 357 men. Men with adjuvant radiation or hormone therapy before the occurrence of biochemical relapse were excluded.
RESULTS: Positive lymph nodes were detected in 17 men in group 1, and in 18 in group 2. In more than half of the patients (19/35) these nodes were found outside the region of standard lymphadenectomy. Men with node-positive disease had a higher biochemical relapse rate (P < 0.001). When the tumour was organ-confined and well differentiated in node-positive disease (Gleason score < or = 6) the biochemical relapse rate was lower than in men with higher tumour stage and grade.
CONCLUSIONS: When dissecting pelvic lymph nodes, extended or sentinel lymphadenectomy should be preferred. Removing the diseased nodes could improve the PSA progression-free survival, especially in well differentiated organ-confined disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686707     DOI: 10.1111/j.1464-410X.2006.06166.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

1.  Why all prostate cancer surgery should include an adequate lymph node dissection.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

2.  Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Authors:  Hillary M Ross; Oleksandr N Kryvenko; Janet E Cowan; Jeffry P Simko; Thomas M Wheeler; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

3.  Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: influence of the dose of radiolabelled colloid to avoid failure of the procedure.

Authors:  Isabelle Brenot-Rossi; Dominique Rossi; Benjamin Esterni; Serge Brunelle; Guillaume Chuto; Cyrille Bastide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-09       Impact factor: 9.236

Review 4.  A systematic review and meta-analysis of comparative studies on the efficacy of extended pelvic lymph node dissection in patients with clinically localized prostatic carcinoma.

Authors:  Liang Gao; Lu Yang; Xiao Lv; Siyuan Bu; Fan Wan; Shengqiang Qian; Qiang Wei; Ping Han; Tianyong Fan
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-27       Impact factor: 4.553

5.  Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.

Authors:  Christian von Bodman; Guilherme Godoy; Daher C Chade; Angel Cronin; Laura J Tafe; Samson W Fine; Vincent Laudone; Peter T Scardino; James A Eastham
Journal:  J Urol       Date:  2010-05-15       Impact factor: 7.450

Review 6.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

7.  Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.

Authors:  A-C Müller; J Lütjens; M Alber; F Eckert; M Bamberg; D Schilling; C Belka; U Ganswindt
Journal:  Strahlenther Onkol       Date:  2012-10-11       Impact factor: 3.621

8.  Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.

Authors:  Peter Jantscheff; Vittorio Ziroli; Norbert Esser; Ralph Graeser; Jessica Kluth; Alena Sukolinskaya; Lenka A Taylor; Clemens Unger; Ulrich Massing
Journal:  Clin Exp Metastasis       Date:  2009-09-26       Impact factor: 5.150

Review 9.  Extended lymph node dissection for prostate cancer.

Authors:  Stephan Jeschke; Fiona C Burkhard; Ramesh Thurairaja; Nivedita Dhar; Urs E Studer
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

10.  Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.

Authors:  Daniela B Husarik; Raymond Miralbell; Markus Dubs; Hubert John; Olivier T Giger; Albert Gelet; Tibor Cservenyàk; Thomas F Hany
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.